In Business 29 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 29 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[Elidel] [SDZ-ASM-981]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
5 mg |
49 |
38 |
32 |
4300 |
| ||
|
10 mg |
74 |
57 |
48 |
6500 |
| ||
|
25 mg |
142 |
110 |
92 |
12400 |
| ||
|
50 mg |
225 |
174 |
146 |
19700 |
| ||
|
100 mg |
385 |
298 |
250 |
33700 |
| ||
|
200 mg |
625 |
484 |
405 |
54700 |
| ||
|
300 mg |
792 |
613 |
513 |
69300 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Prices and Purity — LC Labs vs. Other Suppliers |
|---|
M.W. 810.45
C43H68ClNO11
[137071-32-0]
M.I. 14: 7429
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO and ethanol, up to about 25 mg/mL. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Pimecrolimus, a rapamycin (sirolimus) derivative, is a cell-selective inhibitor of inflammatory cytokines developed for the treatment of inflammatory skin diseases, such as allergic contact dermatitis, atopic dermatitis, plaque-type psoriasis, and irritant contact dermatitis. It reduces the production of inflammatory cytokines in T cells and mast cells and inhibits the release of preformed inflammatory mediators from mast cells. Stuetz, A., et al. "Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity." Semin. Cutan. Med. Surg. 20: 233-241 (2001).
In 13 of 26 (50%) lesions of vitiligo, repigmentation was noted after a 6 month treatment of 1% pimecrolimus with a median percentage of repigmentation of 72.9% (interquartile range: 30.5-98.3%). Total affected body surface area and duration of vitiligo tended to be inversely correlated with the success rate of treatment. Boone, B., et al. "Topical pimecrolimus in the treatment of vitiligo." Eur. J. Dermatol. 17: 55-61 (2007).
Pimecrolimus is active against mild to moderate atopic dermatitis in adults and children aged ≥ 2 years. Pimecrolimus improved the signs and symptoms of atopic dermatitis and postponed time to a major flare. Hebert, A.A. "Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis." Clin. Ther. 28: 1972-1982 (2006).
Pimecrolimus is the active ingredient in the drug sold under the trade name Elidel®. This drug is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream. NOTE: The pimecrolimus sold by LC Laboratories is NOT Elidel®, and is NOT for human use.
Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
Not available in some countries; not available to some institutions; not available for some uses.
Please see also our other standard immunosuppressant products:
© 1990-2010 LC Laboratories All rights reserved.
